FilingReader Intelligence
CSPC Innovation posts 102% loss increase despite revenue growth
August 15, 2025 at 09:49 AM UTC•By FilingReader AI
CSPC Innovation Pharmaceutical reported a net loss of 2.75 billion yuan, up 102% year-over-year, despite operating revenue rising 7.99% to 1.05 billion yuan.
The company increased R&D spending by 80.81% to 455 million yuan, primarily for biotech innovation. Liu Gangsan retired as vice general manager, with Hui Xiwu appointed as replacement.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Announcement regarding the increase in the estimated amount of daily related-party transactions for the year 2025August 15, 2025 at 08:00 AM UTC
Announcement of resolutions from the 25th meeting of the sixth board of directorsAugust 15, 2025 at 08:00 AM UTC
Special report on the deposit, management, and use of raised funds for the first half of 2025August 15, 2025 at 08:00 AM UTC
Summary table of non-operating fund occupation and other related party fund transactions for the first half of 2025August 15, 2025 at 08:00 AM UTC
2025 semi-annual report summaryAugust 15, 2025 at 08:00 AM UTC
Progress announcement on using part of idle raised funds for cash managementAugust 15, 2025 at 08:00 AM UTC
SZSE:300765•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when CSPC Innovation Pharmaceutical publishes news
Free account required • Unsubscribe anytime